Short Sellers Get Even More Ambitious Against Biotech Leaders

Photo of Chris Lange
By Chris Lange Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

The short interest data are out for the May 15 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can make or break them. A single failed clinical trial can mean disaster for a stock. 24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies.

The May 15 short interest data have been compared with the previous figures, and for most of the selected stocks, short interest is down.

Amgen Inc. (NASDAQ: AMGN) saw its short interest drop to 8.85 million shares from the previous reading of 9.21 million. Shares closed Wednesday at $160.44, in a 52-week trading range of $114.93 to $173.60.

Biogen Inc. (NASDAQ: BIIB) saw its short interest increase to 3.04 million shares from the previous 2.98 million. The company was slowly approaching the lower part of its short interest range from back in November, and now it is seemingly returning to more normalized levels. Shares closed Wednesday at $402.92, within a 52-week trading range of $290.85 to $480.18.

Celgene Corp. (NASDAQ: CELG) short interest increased for this settlement date, to 16.27 million shares. The level for the previous settlement date was 14.00 million. Since March, Celgene has recorded a few of its highest readings of the year, barring a spike last June. However, the current level is the highest short interest reading on the year. Shares of Celgene closed Wednesday at $116.02, in a 52-week range of $75.62 to $129.06.

Gilead Sciences Inc. (NASDAQ: GILD) saw its short interest jump to 60.05 million shares from 55.51 million in the previous period. Shares closed Wednesday at $112.46, in a 52-week trading range of $78.50 to $116.83.

ALSO READ: The 5 Most Shorted Nasdaq Stocks in May

MannKind Corp. (NASDAQ: MNKD) saw its short interest increase to an even higher level on the year, some 112.95 million shares. The previous reading was 100.93 million shares. Short interest for MannKind appears to have steadily increased to its 52-week high as investors remain pessimistic. Shares closed Wednesday at $5.27, in a 52-week trading range of $3.46 to $11.48.

Alexion Pharmaceuticals Inc. (NASDAQ: ALXN) short interest increased a whopping 5 million shares or so to 7.23 million, up from the previous level of 2.98 million. This current level is far and away the highest reading on the year. Shares closed Wednesday at $168.12, in a 52-week range of $150.06 to $203.30.

Photo of Chris Lange
About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

Continue Reading

Top Gaining Stocks

CBOE Vol: 1,568,143
PSKY Vol: 12,285,993
STX Vol: 7,378,346
ORCL Vol: 26,317,675
DDOG Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ Vol: 4,367,433
CLX Vol: 13,260,523
SYK Vol: 4,519,455
MHK Vol: 1,859,865
AMGN Vol: 3,818,618